FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3024830553> ?p ?o ?g. }

• W3024830553 endingPage "557" @default.
• W3024830553 startingPage "552" @default.
• W3024830553 abstract "Objective: To investigate the impact of FLT3-ITD and DNMT3A R882 double mutations to the prognosis of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Methods: FLT3-ITD, DNMT3A, C-kit, CEBPA, FLT3-TKD and NPM1 mutations were detected in 206 newly diagnosed AML patients by Sanger sequencing (M(3) and those received FLT3 inhibitor were excluded). Clinical data of AML patients were retrospectively analyzed to compare the prognosis of each gene mutation group. Results: ①Of 206 patients, 104 were male and 102 female with a median age of 38 (3-63) years, including 6 cases of M(0), 24 cases of M(1), 56 cases of M(2), 39 cases of M(4), 63 cases of M(5), 6 cases of M(6) and 12 unclassified cases. ②All 206 patients were divided into four groups according to the mutation gene at the time of diagnosis: FLT3-ITD(+) DNMT3A R882(+) group (group A), FLT3-ITD(+) DNMT3A R882(-) group (group B), FLT3-ITD(-) DNMT3A R882(+) group (group C) and FLT3-ITD(-) DNMT3A R882(-) groups (group D). Gender, leukocyte count at diagnosis, chromosome karyotype, the median age, FAB classification, disease status prior to transplantation, type of donor, conditioning regimen and GVHD were not significantly different between four groups (P>0.05). ③The 2-year cumulative recurrence rate (CIR) of group A was significantly higher than that of other groups [group A (72.2±2.6)%, group B (38.6±0.6)%, group C (36.8±1.6)%, group D (27.8±0.1)%, respectively, P<0.05], while the 2-year overall survival (OS) rate and 2-year leukocyte-free survival (LFS) rate were lower than those of other groups [group A (30.9±13.3)%, (11.3±10.2)%; group B (67.5±7.8)%, (47.9±8.4)%; group C (61.4±12.4)%, (56.8±12.5)%; group D (80.1±3.7)%, (79.7±3.6)%, respectively, P<0.05]. Conclusion: AML patients with FLT3-ITD and DNMT3A R882 double mutations had a very high CIR and low OS, LFS after transplantation.目的： 探讨FLT3-ITD和DNMT3A R882双突变对急性髓系白血病（AML）患者allo-HSCT预后的影响。 方法： 使用直接测序法检测206例接受allo-HSCT的AML患者（M(3)和使用分子靶向药物索拉菲尼的病例除外）初诊时骨髓中常见的基因突变组套（包括FLT3-ITD、DNMT3A、c-kit、CEBPA、FLT3-TKD、NPM1），回顾性分析患者的临床资料，比较各基因突变组的移植预后。 结果： ①206例AML患者中男104例，女102例，中位年龄38（3~63）岁。FAB分型：M(0) 6例，M(1) 24例，M(2) 56例，M(4) 39例，M(5) 63例，M(6) 6例，不能分类12例。②全部206例患者根据初诊时的突变基因情况分为4组：FLT3-ITD(+) DNMT3A R882(+)组（A组）19例，FLT3-ITD(+) DNMT3A R882(－)组（B组）38例，FLT3-ITD(－)DNMT3A R882(+)组（C组）21例，FLT3-ITD(－)DNMT3A R882(－)组（D组）128例。四组间性别、年龄、初诊时白细胞计数、FAB分型、移植前疾病状态、染色体核型、供者类型、预处理方案及GVHD发生率比较，差异无统计学意义（P>0.05）。③A组和B、C、D组比较，2年累积复发率较高[分别为（72.2±2.6）%、（38.6±0.6）%、（36.8±1.6）%、（27.8±0.1）%，P值均<0.05]，总生存率较低[分别为（30.9±13.3）%、（67.5±7.8）%、（61.4±12.4）%、（80.1±3.7）%，P值均<0.05]，无白血病生存率较低[分别为（11.3±10.2）%、（47.9±8.4）%、（56.8±12.5）%、（79.7±3.6）%，P值均<0.05]。 结论： 伴有FLT3-ITD与DNMT3A R882双突变的AML患者移植后累积复发率较高，总生存率和无白血病生存率较差。." @default.
• W3024830553 created "2020-05-21" @default.
• W3024830553 creator A5000141893 @default.
• W3024830553 creator A5004840938 @default.
• W3024830553 creator A5021441720 @default.
• W3024830553 creator A5030108757 @default.
• W3024830553 creator A5045516426 @default.
• W3024830553 creator A5048323168 @default.
• W3024830553 creator A5049192788 @default.
• W3024830553 creator A5059205697 @default.
• W3024830553 creator A5063800607 @default.
• W3024830553 creator A5066073550 @default.
• W3024830553 creator A5066977940 @default.
• W3024830553 creator A5072705231 @default.
• W3024830553 creator A5074002455 @default.
• W3024830553 date "2018-07-14" @default.
• W3024830553 modified "2023-10-16" @default.
• W3024830553 title "[Effect of FLT3-ITD with DNMT3A R882 double-mutation on the prognosis of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation]." @default.
• W3024830553 cites W1601398749 @default.
• W3024830553 cites W1855200385 @default.
• W3024830553 cites W1945115267 @default.
• W3024830553 cites W1966379304 @default.
• W3024830553 cites W2000500838 @default.
• W3024830553 cites W2005802306 @default.
• W3024830553 cites W2009474598 @default.
• W3024830553 cites W2025193307 @default.
• W3024830553 cites W2131225669 @default.
• W3024830553 cites W2155104532 @default.
• W3024830553 cites W2337995955 @default.
• W3024830553 cites W2346560849 @default.
• W3024830553 cites W2410589065 @default.
• W3024830553 cites W2411236576 @default.
• W3024830553 cites W2419419103 @default.
• W3024830553 cites W2475490941 @default.
• W3024830553 cites W2572106963 @default.
• W3024830553 doi "https://doi.org/10.3760/cma.j.issn.0253-2727.2018.07.005" @default.
• W3024830553 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7342207" @default.
• W3024830553 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30122013" @default.
• W3024830553 hasPublicationYear "2018" @default.
• W3024830553 type Work @default.
• W3024830553 sameAs 3024830553 @default.
• W3024830553 citedByCount "2" @default.
• W3024830553 countsByYear W30248305532019 @default.
• W3024830553 countsByYear W30248305532023 @default.
• W3024830553 crossrefType "journal-article" @default.
• W3024830553 hasAuthorship W3024830553A5000141893 @default.
• W3024830553 hasAuthorship W3024830553A5004840938 @default.
• W3024830553 hasAuthorship W3024830553A5021441720 @default.
• W3024830553 hasAuthorship W3024830553A5030108757 @default.
• W3024830553 hasAuthorship W3024830553A5045516426 @default.
• W3024830553 hasAuthorship W3024830553A5048323168 @default.
• W3024830553 hasAuthorship W3024830553A5049192788 @default.
• W3024830553 hasAuthorship W3024830553A5059205697 @default.
• W3024830553 hasAuthorship W3024830553A5063800607 @default.
• W3024830553 hasAuthorship W3024830553A5066073550 @default.
• W3024830553 hasAuthorship W3024830553A5066977940 @default.
• W3024830553 hasAuthorship W3024830553A5072705231 @default.
• W3024830553 hasAuthorship W3024830553A5074002455 @default.
• W3024830553 hasConcept C104317684 @default.
• W3024830553 hasConcept C126322002 @default.
• W3024830553 hasConcept C143998085 @default.
• W3024830553 hasConcept C2483381 @default.
• W3024830553 hasConcept C2777408962 @default.
• W3024830553 hasConcept C2778461978 @default.
• W3024830553 hasConcept C2778729363 @default.
• W3024830553 hasConcept C28328180 @default.
• W3024830553 hasConcept C2911091166 @default.
• W3024830553 hasConcept C30481170 @default.
• W3024830553 hasConcept C45091340 @default.
• W3024830553 hasConcept C501734568 @default.
• W3024830553 hasConcept C53226629 @default.
• W3024830553 hasConcept C54355233 @default.
• W3024830553 hasConcept C71924100 @default.
• W3024830553 hasConcept C86803240 @default.
• W3024830553 hasConcept C90924648 @default.
• W3024830553 hasConceptScore W3024830553C104317684 @default.
• W3024830553 hasConceptScore W3024830553C126322002 @default.
• W3024830553 hasConceptScore W3024830553C143998085 @default.
• W3024830553 hasConceptScore W3024830553C2483381 @default.
• W3024830553 hasConceptScore W3024830553C2777408962 @default.
• W3024830553 hasConceptScore W3024830553C2778461978 @default.
• W3024830553 hasConceptScore W3024830553C2778729363 @default.
• W3024830553 hasConceptScore W3024830553C28328180 @default.
• W3024830553 hasConceptScore W3024830553C2911091166 @default.
• W3024830553 hasConceptScore W3024830553C30481170 @default.
• W3024830553 hasConceptScore W3024830553C45091340 @default.
• W3024830553 hasConceptScore W3024830553C501734568 @default.
• W3024830553 hasConceptScore W3024830553C53226629 @default.
• W3024830553 hasConceptScore W3024830553C54355233 @default.
• W3024830553 hasConceptScore W3024830553C71924100 @default.
• W3024830553 hasConceptScore W3024830553C86803240 @default.
• W3024830553 hasConceptScore W3024830553C90924648 @default.
• W3024830553 hasIssue "7" @default.
• W3024830553 hasLocation W30248305531 @default.
• W3024830553 hasOpenAccess W3024830553 @default.
• W3024830553 hasPrimaryLocation W30248305531 @default.
• W3024830553 hasRelatedWork W1840668697 @default.
• W3024830553 hasRelatedWork W2007520265 @default.

• next